Literature DB >> 9192941

In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices.

P W Barry1, C O'Callaghan.   

Abstract

Metered-dose inhalers (MDIs) are currently being reformulated to contain hydrofluoroalkanes (HFAs), which do not damage the Earth's ozone layer. As different formulations of inhaled drugs may behave differently when used with spacer devices, we wished to determine the amount of salbutamol available for inhalation from a conventional metered-dose inhaler (Ventolin) and a new HFA-containing formulation (Airomir), when used with two different spacers. A glass multistage liquid impinger was used to determine the amount of salbutamol delivered from the inhalers used with the Aerochamber and the Nebuhaler spacer devices. High speed video-recordings of inhaler actuation into air were made, and the speed of the aerosol and the aerosol cloud volume were measured. More salbutamol in small particles (<5 microm) was delivered from the Airomir MDI than the Ventolin MDI, when used with the Aerochamber (40.4 (95% confidence interval (95% CI) 31.2-49.6) versus 19.5 (19.0-20.0) microg) and the Nebuhaler (42.1 (36.3-47.9) versus 24.6 (23.3-25.8) microg). The aerosol cloud from the Airomir MDI was slower than the Ventolin aerosol, and 60 ms after actuation had travelled 186 mm, whereas the Ventolin aerosol had travelled 320 mm. At the same time, the Airomir aerosol occupied a smaller volume than the Ventolin MDI (251 (213-288) versus 695 (608-782) cm3). The hydrofluoroalkane formulation delivers more salbutamol than the conventional formulation when used either with the Aerochamber or Nebuhaler spacer. This may be because less drug is deposited in the spacer from the hydrofluoroalkane formulation, which is emitted from the metered-dose inhaler at a slower speed and occupies a smaller volume than the conventional formulation. The observed difference in drug delivery may be important for patients changing formulations, and in severe asthma, where high doses of salbutamol may be administered through a spacer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192941     DOI: 10.1183/09031936.97.10061345

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers.

Authors:  Hugh D C Smyth; Vance P Beck; Dennis Williams; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2004-02-10       Impact factor: 3.246

2.  Aerosol profile extracted from spacers as a determinant of actual dose.

Authors:  Sylvia Verbanck; Chris Vervaet; Daniël Schuermans; Walter Vincken
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

3.  Effect of oropharyngeal length in drug lung delivery via suspension pressurized metered dose inhalers.

Authors:  T Ehtezazi; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

Review 4.  Antiasthmatic drug delivery in children.

Authors:  Elizabeth Biggart; Andrew Bush
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Valved holding chamber drug delivery is dependent on breathing pattern and device design.

Authors:  Péter Csonka; Lauri Lehtimäki
Journal:  ERJ Open Res       Date:  2019-02-04

Review 6.  Optimal administration of bronchodilators with valved holding chambers in preschool children: a review of literature.

Authors:  Péter Csonka; Terhi Tapiainen; Mika J Mäkelä; Lauri Lehtimäki
Journal:  Eur J Pediatr       Date:  2021-04-20       Impact factor: 3.183

7.  Potential of a cyclone prototype spacer to improve in vitro dry powder delivery.

Authors:  Irene Parisini; Sean J Cheng; Digby D Symons; Darragh Murnane
Journal:  Pharm Res       Date:  2014-05       Impact factor: 4.200

Review 8.  A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC.

Authors:  Sanjeeva Dissanayake; Jason Suggett
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.